Related references
Note: Only part of the references are listed.Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
Alexander M. M. Eggermont et al.
LANCET ONCOLOGY (2015)
Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Local and Intralesional Therapy of In-Transit Melanoma Metastases
Alessandro Testori et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone:: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
C. Garbe et al.
ANNALS OF ONCOLOGY (2008)
Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update
Kazuyuki Ishihara et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma:: final results of EORTC 18991, a randomised phase III trial
Alexander M. M. Eggermont et al.
LANCET (2008)
A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma
JM Kirkwood et al.
CLINICAL CANCER RESEARCH (2004)
Share Paper
